leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...127128129130131132133134135136137...236237»
  • ||||||||||  temozolomide / Generic mfg., methotrexate / Generic mfg.
    FDA event, Journal:  Peptidomimetic-based identification of FDA approved compounds inhibiting IRE1 activity. (Pubmed Central) -  Jul 28, 2021   
    The inhibitors were verified to have an impact on IRE1 activity in vitro and were tested for their ability to sensitise human cell models of glioblastoma multiforme (GBM) to chemotherapy. We show that all molecules identified sensitise glioblastoma cells to the standard of care chemotherapy temozolomide (TMZ).
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal, PARP Biomarker, IO biomarker:  Systemic treatment of advanced or recurrent biliary tract cancer. (Pubmed Central) -  Jul 28, 2021   
    However, ICIs are still being evaluated in several ongoing studies. Combination therapies have garnered attention because of interactions between signaling pathways of carcinogenesis in BTC.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Observational data, Retrospective data, Journal:  Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database. (Pubmed Central) -  Jul 28, 2021   
    The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the factors associated with the duration of antitumor drug treatment from second-line antiangiogenic therapy in Japan...The most common first-line treatments were FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin) or CAPOX (capecitabine, oxaliplatin) with bevacizumab (presumed RAS-mutant CRC) and FOLFOX with panitumumab (presumed RAS-wild type CRC)...Treatment of advanced CRC in Japan is consistent with both international and Japanese guidelines, but transition rates to subsequent therapies need improvement. In addition to antitumor drug treatment, better ADL, higher body mass index, management of hypertension, and proteinuria tests were associated with continuation of sequential therapy that included antiangiogenic drugs.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal, Circulating Tumor Cells:  Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment. (Pubmed Central) -  Jul 28, 2021   
    Oxaliplatin-fluoropyrimidine combination therapy is the gold standard treatment for patients with stage III colorectal cancer (CRC); however, treatment duration is now under re-evaluation...A significant correlation was demonstrated between microbial DNA detection and both CTCs detection at baseline and CTCs increase between baseline and three months of treatment. To conclude, the current study provides additional evidence of non-inferiority of three over 6 months of treatment, mainly in patients under CAPOX.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  SPTAN1 Expression Predicts Treatment and Survival Outcomes in Colorectal Cancer. (Pubmed Central) -  Jul 28, 2021   
    Taken together, we identify SPTAN1 as a novel prognostic biomarker in CRC and show that SPTAN1 expression levels may predict patient responses to chemotherapy. These investigations illustrate how an affordable, histology-based diagnostic test could directly impact therapeutic decision-making at the bedside.
  • ||||||||||  cisplatin / Generic mfg.
    Review, Journal, IO biomarker:  Chemotherapy for Biliary Tract Cancer in 2021. (Pubmed Central) -  Jul 27, 2021   
    Combination chemotherapy with gemcitabine and cisplatin is currently the standard of care for first-line chemotherapy in advanced cases...In the adjuvant setting, capecitabine monotherapy has become the standard of care in Western countries...Genetic testing is used to check for genetic alterations and molecular-targeted agents and immunotherapy are introduced based on tumor characteristics. In this article, we review the latest evidence of chemotherapy for biliary tract cancer.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    [VIRTUAL] PurIST Pancreatic Cancer Classifier: A 16-RNA Expression Signature Array Comparable to RNAseq () -  Jul 24, 2021 - Abstract #AMP2021AMP_114;    
    The array based PurIST Pancreatic Cancer Classifier has robust performance comparable to full transcriptomic sequencing, and time to report is more rapid. A clinical trial is now underway to assess clinical validity by using this assay to guide selection of chemotherapeutic regimens.
  • ||||||||||  irinotecan / Generic mfg.
    Review, Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker:  Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. (Pubmed Central) -  Jul 22, 2021   
    Major breakthroughs have been achieved in the management of metastatic pancreatic ductal adenocarcinoma (PDAC) with FOLFIRINOX (5-fluorouracil + irinotecan + oxaliplatin) and gemcitabine plus nab-paclitaxel approved as a first-line therapy, although the prognosis is still poor...Although not confirmed in large, prospective trials, gemcitabine alone as a maintenance therapy following induction treatment with gemcitabine plus nab-paclitaxel could be an option, while a small subset of patients with a germline mutation of breast cancer gene (BRCA) can benefit from the polyadenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib...The Food and Drug Administration (FDA) recently approved larotrectinib for patients with any tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and pembrolizumab for patients with a mismatch repair deficiency in a second-line setting, including PDAC. Research focused on targeted therapy and immunotherapy is active and could improve patients' outcomes in the near future.
  • ||||||||||  Tedopi (OSE 2101) / OSE Immunotherapeutics, Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] A randomized non-comparative phase II study of maintenance therapy with FOLFIRI alone or in combination with Tedopi vaccine after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (TEDOPAM – D17-01 PRODIGE 63 STUDY) () -  Jul 22, 2021 - Abstract #ESMO2021ESMO_2765;    
    P2
    It was initially a randomized, non-comparative phase II study with 3 arms: FOLFIRI, Tedopi, Tedopi + nivolumab...Pts with recurrent or advanced, pathologically proven PDAC, ECOG PS 0-1, HLA-A2 genotype and controlled disease after a 4-month (8 cycles) induction course of chemotherapy with FOLFIRINOX or modified FOLFIRINOX are randomized (1:1, stratified on center, tumor stage, best response to FOLFIRINOX) into one of the 2 arms (N=53 Pts/arm): - Arm A (reference arm): maintenance with FOLFIRI (folinic acid 400 mg/m2, irinotecan 180 mg/m2, 5FU bolus 400 mg/m2 + continuous 2400 mg/m2/46h) - Arm B (experimental arm): maintenance with FOLFIRI + OSE2101 (subcutaneous injection on D1 Q3W/6 doses then Q8W until M12 then Q12W up to M24) FOLFIRI in both arms is until disease progression or unacceptable toxicity...Interim analysis after inclusion of 20 Pts in each arm. Translational research to explore prognostic and predictive biomarkers on tumor tissue (initial biopsy and optional re-biopsy at inclusion): RNAseq, mutation burden, immune infiltrates; and in blood (before and on-treatment): cytokine panel, vaccine-antigen specific T-cells, extracellular vesicles.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    [VIRTUAL] Gastric cancer: Data from the AGAMENON-SEOM study () -  Jul 22, 2021 - Abstract #ESMO2021ESMO_2692;    
    The Spanish AGAMENON-SEOM registry includes a representative sample of patients, predominantly first-line treated with platinum and fluoropyrimidine. PFS and OS, influenced by clinical characteristics, reproduced those published in the literature.
  • ||||||||||  Avastin (bevacizumab) / Roche
    [VIRTUAL] FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors () -  Jul 22, 2021 - Abstract #ESMO2021ESMO_1921;    
    The FOLFOX-bevacizumab combination has promising efficacy in patients with progressive metastatic NETs, notably in those with G3 NETs, for which optimal treatment is ill-defined yet. Hence, it could be a relevant alternative to alkylating-based chemotherapy in this setting and should be further explored prospectively.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    [VIRTUAL] Correction of geriatric status in patients with metastatic colorectal cancer () -  Jul 22, 2021 - Abstract #ESMO2021ESMO_1859;    
    Recruitment began in the US in October 2020, and globally in early 2021. The CGS allows to improve not only the geriatric status and tolerability of chemotherapy, but also the direct of treatment (CSR) and long-term (EFS) in patients with mCRC.